EUVIMEDEUVIMED entdecken
Crossref

Branded Versus Generic Antiepileptic Drugs in Epilepsy: Weighing Clinical Impact and Cost Effectiveness

Sandeep Kumar Yadav, Pratiksha Nagesh Kini, AnilKumar Kusnoor, Mujammil Mulla, Satish Karoli, Manjula Gudhoor

International Journal of Pharmaceutical Investigation · 11.06.2026 · 16 (3) · 946-952

DOI: 10.5530/ijpi.20260550 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Pharmaceutical Investigation, online erschienen am 11.06.2026. Verfasst von Sandeep Kumar Yadav und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Yadav, S. K., Kini, P. N., Kusnoor, A., Mulla, M., Karoli, S., & Gudhoor, M. (2026). Branded Versus Generic Antiepileptic Drugs in Epilepsy: Weighing Clinical Impact and Cost Effectiveness. International Journal of Pharmaceutical Investigation, 16(3), 946-952. https://doi.org/10.5530/ijpi.20260550

Vancouver

Yadav SK, Kini PN, Kusnoor A, Mulla M, Karoli S, Gudhoor M. Branded Versus Generic Antiepileptic Drugs in Epilepsy: Weighing Clinical Impact and Cost Effectiveness. International Journal of Pharmaceutical Investigation. 2026;16(3):946-952. doi:10.5530/ijpi.20260550

BibTeX
@article{Yadav2026,
  author = {Yadav, Sandeep Kumar and Kini, Pratiksha Nagesh and Kusnoor, AnilKumar and Mulla, Mujammil and Karoli, Satish and Gudhoor, Manjula},
  title = {Branded Versus Generic Antiepileptic Drugs in Epilepsy: Weighing Clinical Impact and Cost Effectiveness},
  journal = {International Journal of Pharmaceutical Investigation},
  year = {2026},
  volume = {16},
  number = {3},
  pages = {946--952},
  doi = {10.5530/ijpi.20260550}
}
Kostenlos starten →